Goodbody Health Inc (AQSE:GDBY, CSE:GDBY, OTCQB:GDBYF) said revenue rose 52% in the first half of 2022, though the pace slowed towards the end of the period with an easing in demand for Covid PCR tests.
Revenue rose by £2.55mln to £7.40mln (£4.85mln) and though gross profit rose by £1mln, Goodbody said margins were lower due to a more competitive environment with pre-tax losses rising to £1.4mln (£1.27mln).
Non-Covid testing continues to be rolled out to improve revenue by the end of 2022, Goodbody said, while PCR testing and lateral flow tests are still ongoing based on travel requirements.
Aquis-listed Goodbody now has 235 clinics, with over 70% offering blood and other diagnostic testing services. It is also switching its domicile from Canada to Guernsey.
Geremy Thomas, executive chairman, added: "The strategic direction of the group remains focussed on both the expansion of the clinic network and the range of available tests.
"Growth in alternative testing has continued steadily although slower than as originally envisaged due to the current economic environment but we are still positive that due to the synergy of services with the NHS long-term plan the final result will still be as per the original plan."